Koukopoulos Alexia, Calderoni Claudia, Kotzalidis Georgios D, Callovini Tommaso, Moccia Lorenzo, Montanari Silvia, Autullo Gianna, Simonetti Alessio, Pinto Mario, Camardese Giovanni, Sani Gabriele, Janiri Delfina
Department of Life Science, Health and Health Professions, Link Campus University, 00165 Rome, Italy.
Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.
Pharmaceuticals (Basel). 2025 Jun 30;18(7):979. doi: 10.3390/ph18070979.
: Lurasidone ((3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione) is a second-generation antipsychotic approved for schizophrenia and mood disorders. Adolescents and children with bipolar disorder receive treatments that expose them to weight gain and metabolic syndrome. Lurasidone is relatively free from such side effects, so it may constitute a useful alternative for the treatment of these patients. We focused on the use of lurasidone in children and adolescents with bipolar disorder. : On 11 June 2025, we used the following strategy on PubMed: lurasidone AND ("bipolar disorder" OR "bipolar depression" OR mania OR manic). We filtered for humans and ages 0-18 years and included case reports and clinical studies. Similar strategies adapted to each database were used to carry out our systematic review on CINAHL, PsycINFO/PsycARTICLES, Scopus, and the ClinicalTrials.gov register on the same date. We excluded reports without children/adolescent participants, those grouping adult participants with children/adolescents without providing data separately, reviews, and opinions/editorials with no data. Eligibility was determined through Delphi rounds; it was required that consensus was reached among all authors. We followed the PRISMA-2020 Statement. : Our search produced 38 results on PubMed on 11 June 2025. We included four case reports/series and five studies. One additional eligible study emerged from our Scopus inquiry, raising the number of eligible studies to six. One case series was moderately positive; one case report was neutral, another was positive, and one reported the induction of mania. The six longitudinal studies involved 16,735 participants and showed generally good efficacy. : The use of lurasidone in adolescents/children with bipolar disorder obtains favorable results regarding the excitatory and depressive symptoms of bipolar disorder with no significant side effects.
鲁拉西酮（(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-苯并异噻唑-3-基)哌嗪-1-基甲基]环己基甲基}六氢-4,7-亚甲基-2H-异吲哚-1,3-二酮）是一种已被批准用于治疗精神分裂症和情绪障碍的第二代抗精神病药物。患有双相情感障碍的青少年和儿童接受的治疗会使他们面临体重增加和代谢综合征的风险。鲁拉西酮相对没有此类副作用，因此它可能成为治疗这些患者的一种有用的替代药物。我们重点关注鲁拉西酮在患有双相情感障碍的儿童和青少年中的应用。：2025年6月11日，我们在PubMed上采用了以下检索策略：鲁拉西酮 AND（“双相情感障碍”或“双相抑郁”或躁狂或躁狂症）。我们筛选了人类及0至18岁的年龄范围，并纳入了病例报告和临床研究。在同一天，我们对CINAHL、PsycINFO/PsycARTICLES、Scopus以及ClinicalTrials.gov注册库进行系统评价时，采用了适用于每个数据库的类似策略。我们排除了没有儿童/青少年参与者的报告、将成人参与者与儿童/青少年归为一组但未分别提供数据的报告、综述以及没有数据的观点/社论。通过德尔菲轮次确定纳入标准；要求所有作者达成共识。我们遵循PRISMA - 2020声明。：我们的检索在2025年6月11日的PubMed上产生了38条结果。我们纳入了4篇病例报告/系列和5项研究。我们在Scopus检索中又发现了1项符合条件的研究，使符合条件的研究数量增至6项。1个病例系列呈中度阳性；1篇病例报告为中性，另一篇为阳性，还有1篇报告诱发了躁狂症。这6项纵向研究涉及16,735名参与者，总体显示出良好的疗效。：在患有双相情感障碍的青少年/儿童中使用鲁拉西酮，对于双相情感障碍的兴奋和抑郁症状取得了良好效果，且无显著副作用。
